 - Use of biologic response modifiers within the following periods prior to Day 1: 4 weeks for Kineret anakinra and Enbrel etanercept; 12 weeks for Remicade infliximab, Humira adalimumab, Simponi golimumab, Orencia abatacept, Actemra tocilizumab, or Cimzia certolizumab; 12 months for Rituxan rituximab. 